Summary

The global Anti-Parkinson's Disease Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Antiparkinsonian drugs are a class of drugs used to treat Parkinson's disease (also known as Parkinson's disease). Parkinson's disease is a chronic, progressive neurodegenerative disease characterized by symptoms such as tremors, muscle stiffness, slow movements and impaired balance. These symptoms are primarily caused by decreased levels of a neurotransmitter called dopamine in the brain.
United States market for Anti-Parkinson's Disease Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Anti-Parkinson's Disease Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Anti-Parkinson's Disease Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Anti-Parkinson's Disease Drugs players cover Guangzhou Kanghe Pharmaceutical Co., Ltd., Tianjin Lisheng Pharmaceutical Co., Ltd., Changzhou Kangpu Pharmaceutical Co., Ltd., Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd., Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Anti-Parkinson's Disease Drugs Industry Forecast” looks at past sales and reviews total world Anti-Parkinson's Disease Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-Parkinson's Disease Drugs sales for 2026 through 2032. With Anti-Parkinson's Disease Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Parkinson's Disease Drugs industry.
This Insight Report provides a comprehensive analysis of the global Anti-Parkinson's Disease Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Parkinson's Disease Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-Parkinson's Disease Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Parkinson's Disease Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Parkinson's Disease Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Parkinson's Disease Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Anticholinergics
Dopaminergics
Segmentation by Application:
Hospital
Clinic
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Guangzhou Kanghe Pharmaceutical Co., Ltd.
Tianjin Lisheng Pharmaceutical Co., Ltd.
Changzhou Kangpu Pharmaceutical Co., Ltd.
Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
Hunan Zhongnan Pharmaceutical Co., Ltd.
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Ningbo Dahongying Pharmaceutical Co., Ltd.
Beijing Fuyuan Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Hangzhou Guoguang Pharmaceutical Co., Ltd.
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Kirin
Astellas Pharma
Desitin Arzneimittel
Endo International plc
Roche Holding AG
Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
Bausch Health
Key Questions Addressed in this Report
What is the 10-year outlook for the global Anti-Parkinson's Disease Drugs market?
What factors are driving Anti-Parkinson's Disease Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Parkinson's Disease Drugs market opportunities vary by end market size?
How does Anti-Parkinson's Disease Drugs break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Anti-Parkinson's Disease Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Anti-Parkinson's Disease Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Anti-Parkinson's Disease Drugs by Country/Region, 2021, 2025 & 2032
2.2 Anti-Parkinson's Disease Drugs Segment by Type
2.2.1 Anticholinergics
2.2.2 Dopaminergics
2.2.3 Anti-Parkinson's Disease Drugs Sales by Type
2.2.3.1 Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026)
2.2.3.2 Global Anti-Parkinson's Disease Drugs Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Anti-Parkinson's Disease Drugs Sale Price by Type (2021-2026)
2.3 Anti-Parkinson's Disease Drugs Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Pharmacy
2.3.4 Other
2.3.5 Anti-Parkinson's Disease Drugs Sales by Application
2.3.5.1 Global Anti-Parkinson's Disease Drugs Sale Market Share by Application (2021-2026)
2.3.5.2 Global Anti-Parkinson's Disease Drugs Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Anti-Parkinson's Disease Drugs Sale Price by Application (2021-2026)
3 Global by Company
3.1 Global Anti-Parkinson's Disease Drugs Breakdown Data by Company
3.1.1 Global Anti-Parkinson's Disease Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Anti-Parkinson's Disease Drugs Sales Market Share by Company (2021-2026)
3.2 Global Anti-Parkinson's Disease Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Anti-Parkinson's Disease Drugs Revenue by Company (2021-2026)
3.2.2 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Anti-Parkinson's Disease Drugs Sale Price by Company
3.4 Key Manufacturers Anti-Parkinson's Disease Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-Parkinson's Disease Drugs Product Location Distribution
3.4.2 Players Anti-Parkinson's Disease Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Anti-Parkinson's Disease Drugs by Geographic Region
4.1 World Historic Anti-Parkinson's Disease Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Anti-Parkinson's Disease Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Anti-Parkinson's Disease Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Anti-Parkinson's Disease Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Anti-Parkinson's Disease Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Anti-Parkinson's Disease Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-Parkinson's Disease Drugs Sales Growth
4.4 APAC Anti-Parkinson's Disease Drugs Sales Growth
4.5 Europe Anti-Parkinson's Disease Drugs Sales Growth
4.6 Middle East & Africa Anti-Parkinson's Disease Drugs Sales Growth
5 Americas
5.1 Americas Anti-Parkinson's Disease Drugs Sales by Country
5.1.1 Americas Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
5.1.2 Americas Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026)
5.2 Americas Anti-Parkinson's Disease Drugs Sales by Type (2021-2026)
5.3 Americas Anti-Parkinson's Disease Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-Parkinson's Disease Drugs Sales by Region
6.1.1 APAC Anti-Parkinson's Disease Drugs Sales by Region (2021-2026)
6.1.2 APAC Anti-Parkinson's Disease Drugs Revenue by Region (2021-2026)
6.2 APAC Anti-Parkinson's Disease Drugs Sales by Type (2021-2026)
6.3 APAC Anti-Parkinson's Disease Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Anti-Parkinson's Disease Drugs by Country
7.1.1 Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
7.1.2 Europe Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026)
7.2 Europe Anti-Parkinson's Disease Drugs Sales by Type (2021-2026)
7.3 Europe Anti-Parkinson's Disease Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Anti-Parkinson's Disease Drugs by Country
8.1.1 Middle East & Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Anti-Parkinson's Disease Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Anti-Parkinson's Disease Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-Parkinson's Disease Drugs
10.3 Manufacturing Process Analysis of Anti-Parkinson's Disease Drugs
10.4 Industry Chain Structure of Anti-Parkinson's Disease Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-Parkinson's Disease Drugs Distributors
11.3 Anti-Parkinson's Disease Drugs Customer
12 World Forecast Review for Anti-Parkinson's Disease Drugs by Geographic Region
12.1 Global Anti-Parkinson's Disease Drugs Market Size Forecast by Region
12.1.1 Global Anti-Parkinson's Disease Drugs Forecast by Region (2027-2032)
12.1.2 Global Anti-Parkinson's Disease Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Anti-Parkinson's Disease Drugs Forecast by Type (2027-2032)
12.7 Global Anti-Parkinson's Disease Drugs Forecast by Application (2027-2032)
13 Key Players Analysis
13.1 Guangzhou Kanghe Pharmaceutical Co., Ltd.
13.1.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information
13.1.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.1.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Main Business Overview
13.1.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Latest Developments
13.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
13.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information
13.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Main Business Overview
13.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Latest Developments
13.3 Changzhou Kangpu Pharmaceutical Co., Ltd.
13.3.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information
13.3.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.3.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Main Business Overview
13.3.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Latest Developments
13.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
13.4.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information
13.4.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.4.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Main Business Overview
13.4.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Latest Developments
13.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
13.5.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information
13.5.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.5.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Main Business Overview
13.5.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Latest Developments
13.6 Hunan Zhongnan Pharmaceutical Co., Ltd.
13.6.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information
13.6.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.6.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Main Business Overview
13.6.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Latest Developments
13.7 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
13.7.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
13.7.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.7.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Main Business Overview
13.7.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Latest Developments
13.8 Ningbo Dahongying Pharmaceutical Co., Ltd.
13.8.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information
13.8.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.8.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Main Business Overview
13.8.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Latest Developments
13.9 Beijing Fuyuan Pharmaceutical Co., Ltd.
13.9.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
13.9.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.9.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Latest Developments
13.10 Zhejiang Huahai Pharmaceutical Co., Ltd.
13.10.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
13.10.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.10.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business Overview
13.10.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Latest Developments
13.11 Hangzhou Guoguang Pharmaceutical Co., Ltd.
13.11.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information
13.11.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.11.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Main Business Overview
13.11.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Latest Developments
13.12 Merck
13.12.1 Merck Company Information
13.12.2 Merck Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.12.3 Merck Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Merck Main Business Overview
13.12.5 Merck Latest Developments
13.13 Akorn
13.13.1 Akorn Company Information
13.13.2 Akorn Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.13.3 Akorn Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Akorn Main Business Overview
13.13.5 Akorn Latest Developments
13.14 GSK
13.14.1 GSK Company Information
13.14.2 GSK Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.14.3 GSK Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 GSK Main Business Overview
13.14.5 GSK Latest Developments
13.15 Novartis
13.15.1 Novartis Company Information
13.15.2 Novartis Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.15.3 Novartis Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Novartis Main Business Overview
13.15.5 Novartis Latest Developments
13.16 Boehringer Ingelheim
13.16.1 Boehringer Ingelheim Company Information
13.16.2 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.16.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Boehringer Ingelheim Main Business Overview
13.16.5 Boehringer Ingelheim Latest Developments
13.17 Teva Pharmaceutical
13.17.1 Teva Pharmaceutical Company Information
13.17.2 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.17.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Teva Pharmaceutical Main Business Overview
13.17.5 Teva Pharmaceutical Latest Developments
13.18 Abbvie
13.18.1 Abbvie Company Information
13.18.2 Abbvie Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.18.3 Abbvie Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Abbvie Main Business Overview
13.18.5 Abbvie Latest Developments
13.19 Kyowa Kirin
13.19.1 Kyowa Kirin Company Information
13.19.2 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.19.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Kyowa Kirin Main Business Overview
13.19.5 Kyowa Kirin Latest Developments
13.20 Astellas Pharma
13.20.1 Astellas Pharma Company Information
13.20.2 Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.20.3 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Astellas Pharma Main Business Overview
13.20.5 Astellas Pharma Latest Developments
13.21 Desitin Arzneimittel
13.21.1 Desitin Arzneimittel Company Information
13.21.2 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.21.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Desitin Arzneimittel Main Business Overview
13.21.5 Desitin Arzneimittel Latest Developments
13.22 Endo International plc
13.22.1 Endo International plc Company Information
13.22.2 Endo International plc Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.22.3 Endo International plc Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Endo International plc Main Business Overview
13.22.5 Endo International plc Latest Developments
13.23 Roche Holding AG
13.23.1 Roche Holding AG Company Information
13.23.2 Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.23.3 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Roche Holding AG Main Business Overview
13.23.5 Roche Holding AG Latest Developments
13.24 Lundbeck
13.24.1 Lundbeck Company Information
13.24.2 Lundbeck Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.24.3 Lundbeck Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Lundbeck Main Business Overview
13.24.5 Lundbeck Latest Developments
13.25 Valeant
13.25.1 Valeant Company Information
13.25.2 Valeant Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.25.3 Valeant Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Valeant Main Business Overview
13.25.5 Valeant Latest Developments
13.26 Apokyn
13.26.1 Apokyn Company Information
13.26.2 Apokyn Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.26.3 Apokyn Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Apokyn Main Business Overview
13.26.5 Apokyn Latest Developments
13.27 Orion
13.27.1 Orion Company Information
13.27.2 Orion Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.27.3 Orion Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.27.4 Orion Main Business Overview
13.27.5 Orion Latest Developments
13.28 Stada Arzneimittel
13.28.1 Stada Arzneimittel Company Information
13.28.2 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.28.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.28.4 Stada Arzneimittel Main Business Overview
13.28.5 Stada Arzneimittel Latest Developments
13.29 Bausch Health
13.29.1 Bausch Health Company Information
13.29.2 Bausch Health Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
13.29.3 Bausch Health Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.29.4 Bausch Health Main Business Overview
13.29.5 Bausch Health Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Anti-Parkinson's Disease Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Anti-Parkinson's Disease Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Anticholinergics
Table 4. Major Players of Dopaminergics
Table 5. Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 6. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026)
Table 7. Global Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & ($ million)
Table 8. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2026)
Table 9. Global Anti-Parkinson's Disease Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Anti-Parkinson's Disease Drugs Sale by Application (2021-2026) & (K Units)
Table 11. Global Anti-Parkinson's Disease Drugs Sale Market Share by Application (2021-2026)
Table 12. Global Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & ($ million)
Table 13. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2026)
Table 14. Global Anti-Parkinson's Disease Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Anti-Parkinson's Disease Drugs Sales by Company (2021-2026) & (K Units)
Table 16. Global Anti-Parkinson's Disease Drugs Sales Market Share by Company (2021-2026)
Table 17. Global Anti-Parkinson's Disease Drugs Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Company (2021-2026)
Table 19. Global Anti-Parkinson's Disease Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Anti-Parkinson's Disease Drugs Producing Area Distribution and Sales Area
Table 21. Players Anti-Parkinson's Disease Drugs Products Offered
Table 22. Anti-Parkinson's Disease Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Anti-Parkinson's Disease Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Anti-Parkinson's Disease Drugs Sales Market Share Geographic Region (2021-2026)
Table 27. Global Anti-Parkinson's Disease Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Anti-Parkinson's Disease Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Anti-Parkinson's Disease Drugs Sales Market Share by Country/Region (2021-2026)
Table 31. Global Anti-Parkinson's Disease Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 34. Americas Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026)
Table 35. Americas Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 37. Americas Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 38. APAC Anti-Parkinson's Disease Drugs Sales by Region (2021-2026) & (K Units)
Table 39. APAC Anti-Parkinson's Disease Drugs Sales Market Share by Region (2021-2026)
Table 40. APAC Anti-Parkinson's Disease Drugs Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 42. APAC Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 43. Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 44. Europe Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 46. Europe Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Anti-Parkinson's Disease Drugs
Table 52. Key Market Challenges & Risks of Anti-Parkinson's Disease Drugs
Table 53. Key Industry Trends of Anti-Parkinson's Disease Drugs
Table 54. Anti-Parkinson's Disease Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Anti-Parkinson's Disease Drugs Distributors List
Table 57. Anti-Parkinson's Disease Drugs Customer List
Table 58. Global Anti-Parkinson's Disease Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Anti-Parkinson's Disease Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Anti-Parkinson's Disease Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Anti-Parkinson's Disease Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Anti-Parkinson's Disease Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Anti-Parkinson's Disease Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Anti-Parkinson's Disease Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Anti-Parkinson's Disease Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Anti-Parkinson's Disease Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Anti-Parkinson's Disease Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Anti-Parkinson's Disease Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Guangzhou Kanghe Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 74. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Guangzhou Kanghe Pharmaceutical Co., Ltd. Main Business
Table 76. Guangzhou Kanghe Pharmaceutical Co., Ltd. Latest Developments
Table 77. Tianjin Lisheng Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 79. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Tianjin Lisheng Pharmaceutical Co., Ltd. Main Business
Table 81. Tianjin Lisheng Pharmaceutical Co., Ltd. Latest Developments
Table 82. Changzhou Kangpu Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 84. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Changzhou Kangpu Pharmaceutical Co., Ltd. Main Business
Table 86. Changzhou Kangpu Pharmaceutical Co., Ltd. Latest Developments
Table 87. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 89. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Main Business
Table 91. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Latest Developments
Table 92. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 94. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Main Business
Table 96. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Latest Developments
Table 97. Hunan Zhongnan Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 99. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Hunan Zhongnan Pharmaceutical Co., Ltd. Main Business
Table 101. Hunan Zhongnan Pharmaceutical Co., Ltd. Latest Developments
Table 102. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 104. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Main Business
Table 106. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Latest Developments
Table 107. Ningbo Dahongying Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 109. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Ningbo Dahongying Pharmaceutical Co., Ltd. Main Business
Table 111. Ningbo Dahongying Pharmaceutical Co., Ltd. Latest Developments
Table 112. Beijing Fuyuan Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 114. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Beijing Fuyuan Pharmaceutical Co., Ltd. Main Business
Table 116. Beijing Fuyuan Pharmaceutical Co., Ltd. Latest Developments
Table 117. Zhejiang Huahai Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 119. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business
Table 121. Zhejiang Huahai Pharmaceutical Co., Ltd. Latest Developments
Table 122. Hangzhou Guoguang Pharmaceutical Co., Ltd. Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 124. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Hangzhou Guoguang Pharmaceutical Co., Ltd. Main Business
Table 126. Hangzhou Guoguang Pharmaceutical Co., Ltd. Latest Developments
Table 127. Merck Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Merck Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 129. Merck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Merck Main Business
Table 131. Merck Latest Developments
Table 132. Akorn Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. Akorn Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 134. Akorn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Akorn Main Business
Table 136. Akorn Latest Developments
Table 137. GSK Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. GSK Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 139. GSK Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. GSK Main Business
Table 141. GSK Latest Developments
Table 142. Novartis Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 143. Novartis Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 144. Novartis Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Novartis Main Business
Table 146. Novartis Latest Developments
Table 147. Boehringer Ingelheim Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 148. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 149. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. Boehringer Ingelheim Main Business
Table 151. Boehringer Ingelheim Latest Developments
Table 152. Teva Pharmaceutical Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 153. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 154. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Teva Pharmaceutical Main Business
Table 156. Teva Pharmaceutical Latest Developments
Table 157. Abbvie Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 158. Abbvie Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 159. Abbvie Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Abbvie Main Business
Table 161. Abbvie Latest Developments
Table 162. Kyowa Kirin Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 163. Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 164. Kyowa Kirin Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Kyowa Kirin Main Business
Table 166. Kyowa Kirin Latest Developments
Table 167. Astellas Pharma Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 168. Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 169. Astellas Pharma Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. Astellas Pharma Main Business
Table 171. Astellas Pharma Latest Developments
Table 172. Desitin Arzneimittel Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 173. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 174. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 175. Desitin Arzneimittel Main Business
Table 176. Desitin Arzneimittel Latest Developments
Table 177. Endo International plc Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 178. Endo International plc Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 179. Endo International plc Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 180. Endo International plc Main Business
Table 181. Endo International plc Latest Developments
Table 182. Roche Holding AG Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 183. Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 184. Roche Holding AG Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 185. Roche Holding AG Main Business
Table 186. Roche Holding AG Latest Developments
Table 187. Lundbeck Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 188. Lundbeck Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 189. Lundbeck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 190. Lundbeck Main Business
Table 191. Lundbeck Latest Developments
Table 192. Valeant Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 193. Valeant Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 194. Valeant Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 195. Valeant Main Business
Table 196. Valeant Latest Developments
Table 197. Apokyn Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 198. Apokyn Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 199. Apokyn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 200. Apokyn Main Business
Table 201. Apokyn Latest Developments
Table 202. Orion Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 203. Orion Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 204. Orion Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 205. Orion Main Business
Table 206. Orion Latest Developments
Table 207. Stada Arzneimittel Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 208. Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 209. Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 210. Stada Arzneimittel Main Business
Table 211. Stada Arzneimittel Latest Developments
Table 212. Bausch Health Basic Information, Anti-Parkinson's Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 213. Bausch Health Anti-Parkinson's Disease Drugs Product Portfolios and Specifications
Table 214. Bausch Health Anti-Parkinson's Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 215. Bausch Health Main Business
Table 216. Bausch Health Latest Developments


List of Figures
Figure 1. Picture of Anti-Parkinson's Disease Drugs
Figure 2. Anti-Parkinson's Disease Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-Parkinson's Disease Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Anti-Parkinson's Disease Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Anti-Parkinson's Disease Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Anti-Parkinson's Disease Drugs Sales Market Share by Country/Region (2025)
Figure 10. Anti-Parkinson's Disease Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Anticholinergics
Figure 12. Product Picture of Dopaminergics
Figure 13. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type in 2026
Figure 14. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2026)
Figure 15. Anti-Parkinson's Disease Drugs Consumed in Hospital
Figure 16. Global Anti-Parkinson's Disease Drugs Market: Hospital (2021-2026) & (K Units)
Figure 17. Anti-Parkinson's Disease Drugs Consumed in Clinic
Figure 18. Global Anti-Parkinson's Disease Drugs Market: Clinic (2021-2026) & (K Units)
Figure 19. Anti-Parkinson's Disease Drugs Consumed in Pharmacy
Figure 20. Global Anti-Parkinson's Disease Drugs Market: Pharmacy (2021-2026) & (K Units)
Figure 21. Anti-Parkinson's Disease Drugs Consumed in Other
Figure 22. Global Anti-Parkinson's Disease Drugs Market: Other (2021-2026) & (K Units)
Figure 23. Global Anti-Parkinson's Disease Drugs Sale Market Share by Application (2025)
Figure 24. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application in 2026
Figure 25. Anti-Parkinson's Disease Drugs Sales by Company in 2026 (K Units)
Figure 26. Global Anti-Parkinson's Disease Drugs Sales Market Share by Company in 2026
Figure 27. Anti-Parkinson's Disease Drugs Revenue by Company in 2026 ($ millions)
Figure 28. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Company in 2026
Figure 29. Global Anti-Parkinson's Disease Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Anti-Parkinson's Disease Drugs Sales 2021-2026 (K Units)
Figure 32. Americas Anti-Parkinson's Disease Drugs Revenue 2021-2026 ($ millions)
Figure 33. APAC Anti-Parkinson's Disease Drugs Sales 2021-2026 (K Units)
Figure 34. APAC Anti-Parkinson's Disease Drugs Revenue 2021-2026 ($ millions)
Figure 35. Europe Anti-Parkinson's Disease Drugs Sales 2021-2026 (K Units)
Figure 36. Europe Anti-Parkinson's Disease Drugs Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Anti-Parkinson's Disease Drugs Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Anti-Parkinson's Disease Drugs Revenue 2021-2026 ($ millions)
Figure 39. Americas Anti-Parkinson's Disease Drugs Sales Market Share by Country in 2026
Figure 40. Americas Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2026)
Figure 41. Americas Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026)
Figure 42. Americas Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2026)
Figure 43. United States Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Anti-Parkinson's Disease Drugs Sales Market Share by Region in 2026
Figure 48. APAC Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2021-2026)
Figure 49. APAC Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026)
Figure 50. APAC Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2026)
Figure 51. China Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. India Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Anti-Parkinson's Disease Drugs Sales Market Share by Country in 2026
Figure 59. Europe Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2026)
Figure 60. Europe Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026)
Figure 61. Europe Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2026)
Figure 62. Germany Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. France Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2026)
Figure 70. Egypt Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Anti-Parkinson's Disease Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Anti-Parkinson's Disease Drugs in 2026
Figure 76. Manufacturing Process Analysis of Anti-Parkinson's Disease Drugs
Figure 77. Industry Chain Structure of Anti-Parkinson's Disease Drugs
Figure 78. Channels of Distribution
Figure 79. Global Anti-Parkinson's Disease Drugs Sales Market Forecast by Region (2027-2032)
Figure 80. Global Anti-Parkinson's Disease Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Anti-Parkinson's Disease Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Anti-Parkinson's Disease Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Anti-Parkinson's Disease Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Anti-Parkinson's Disease Drugs Revenue Market Share Forecast by Application (2027-2032)